Evidence map›Paper›PMID 25356364›Full record

ArticleNew microbes and new infections2014

High seroprevalence of Borrelia miyamotoi antibodies in forestry workers and individuals suspected of human granulocytic anaplasmosis in the Netherlands.

S Jahfari, T Herremans, A E Platonov, H Kuiper, L S Karan, O Vasilieva, M P G Koopmans, J W R Hovius, H Sprong

Open access · goldAbstract read
In one paragraph

Article in New microbes and new infections, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. HumanPathogens (Basel, Switzerland) · 2023
    Review
  6. Article
  7. Article
  8. Article
  9. Novel approaches for the serodiagnosis of louse-borne relapsing fever.Frontiers in cellular and infection microbiology · 2022
    Article
  10. Article
  11. Article
  12. Microorganisms · 2021
    Review
  13. Article
  14. Article
  15. Emerging Tick-Borne Diseases.Clinical microbiology reviews · 2020
    Review
  16. Article
  17. A newEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

S JahfariCentre for Infectious Disease Control Netherlands, National Institute for Public Health and Environment (RIVM) P.O. Box 1, 3720 BA, Bilthoven, the Netherlands.
T HerremansCentre for Infectious Disease Control Netherlands, National Institute for Public Health and Environment (RIVM) P.O. Box 1, 3720 BA, Bilthoven, the Netherlands.
A E PlatonovCentral Research Institute of Epidemiology Moscow, Russia.
H KuiperFlevoziekenhuis Almere, the Netherlands.
L S KaranCentral Research Institute of Epidemiology Moscow, Russia.
O VasilievaCentral Research Institute of Epidemiology Moscow, Russia.
M P G KoopmansCentre for Infectious Disease Control Netherlands, National Institute for Public Health and Environment (RIVM) P.O. Box 1, 3720 BA, Bilthoven, the Netherlands.
J W R HoviusDepartment of Internal Medicine, Section of Infectious Diseases, Section of Infectious Diseases, Academic Medical Centre Amsterdam, the Netherlands.
H SprongCentre for Infectious Disease Control Netherlands, National Institute for Public Health and Environment (RIVM) P.O. Box 1, 3720 BA, Bilthoven, the Netherlands.
Central Research Institute of Epidemiology · RUAcademic Medical Center · NLFlevoziekenhuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Substantial exposure to Borrelia miyamotoi occurs through bites from Ixodes ricinus ticks in the Netherlands, which also transmit Borrelia burgdorferi sensu lato and Anaplasma phagocytophilum. Direct evidence for B. miyamotoi infection in European populations is scarce. A flu-like illness with high fever, resembling human granulocytic anaplasmosis, has been attributed to B. miyamotoi infections in relatively small groups. Borrelia miyamotoi infections associated with chronic meningoencephalitis have also been described in case reports. Assuming that an IgG antibody response against B. miyamotoi antigens reflects (endured) infection, the seroprevalence in different risk groups was examined. Sera from nine out of ten confirmed B. miyamotoi infections from Russia were found to be positive with the recombinant antigen used, and no significant cross-reactivity was observed in secondary syphilis patients. The seroprevalence in blood donors was set at 2.0% (95% CI 0.4-5.7%). Elevated seroprevalences in individuals with serologically confirmed, 7.4% (2.0-17.9%), or unconfirmed, 8.6% (1.8-23%), Lyme neuroborreliosis were not significantly different from those in blood donors. The prevalence of anti-B. miyamotoi antibodies among forestry workers was 10% (5.3-16.8%) and in patients with serologically unconfirmed but suspected human granulocytic anaplasmosis was 14.6% (9.0-21.8%); these were significantly higher compared with the seroprevalence in blood donors. Our findings indicate that infections with B. miyamotoi occur in tick-exposed individuals in the Netherlands. In addition, B. miyamotoi infections should be considered in patients reporting tick bites and febrile illness with unresolved aetiology in the Netherlands, and other countries where I. ricinus ticks are endemic.

Indexed as

AnaplasmosisBorrelia miyamotoiIxodes ricinusrelapsing feverserology

Identifiers

PMID25356364
PMCPMC4184479
OpenAlexW2131712581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.